Weight medicines and the proposed product
A weight-care quote needs the exact product name. The ingredient, the brand, the form, and the supply route can each affect which question the quote answers.
Which product is in the quote?
Which names refer to approved products?
In the approval record checked November 3, 2026, semaglutide appears as Ozempic and Wegovy, among other application records. Both names now cover tablet and injection forms, so the brand name alone does not identify the form.
Tirzepatide appears as Mounjaro and Zepbound in the FDA records checked November 3, 2026. Their approved uses differ; an ingredient shared across brands does not make every proposed use the same. The hormone called GLP-1 affects appetite and blood sugar. Medicines in this group imitate it.
Ask the clinician to state the exact product and the reason for proposing it. Then ask the insurer about that product and use. Keep the response attached to the prescription details rather than only to the general term weight care.
Is compounded the same as generic?
No. The November 3, 2026 FDA record has no generic of semaglutide or tirzepatide with approval that permits U.S. marketing. A tentative approval means a product meets FDA’s standards but still cannot be sold.
Liraglutide (Victoza, Saxenda) does have FDA-approved generics as of November 3, 2026. Some have approval for weight management. Check the approved use and whether the product is actually available.
The November 3, 2026 FDA promotion guidance rejects presenting a compounded drug as an approved generic. It also rejects calling that preparation the same as a product with approval. Compounded preparations lack the FDA approval that a generic has.
Ask which meaning a service intends when it uses a familiar name. If it means a compounded preparation, request that wording in the quote so the difference remains visible.
Why do shortage claims need a date?
National shortages created a route for certain compounded copies, with different conditions under the pharmacy and outsourcing-facility frameworks. FDA’s account checked November 3, 2026 ties that route to the national shortage listing.
After reassessment, FDA’s December 19, 2024 decision ended the tirzepatide injection shortage. For semaglutide injections, the resolution date was February 21, 2025. Neither appeared on the national shortage list in the record checked November 3, 2026.
FDA distinguishes that national listing from a brief local stock problem. The shortage account checked November 3, 2026 does not let a single pharmacy’s stock answer the national compounding question.
Ask whether the service is describing a past shortage or the dated status that supports its current proposal. A general story about access during shortages can leave that important detail unstated.
What if a newer name appears in the offer?
In the November 3, 2026 check, FDA’s position excludes compounding with cagrilintide or retatrutide under federal law. FDA also says neither ingredient belongs to an approved drug. A claim about research does not supply an approved prescription product.
FDA has also warned that research-labeled GLP-1 products sold to consumers may have unknown quality and may cause harm. That account was checked November 3, 2026.
Take the exact unfamiliar name back to the clinician before comparing a price. Ask what product is proposed, its status, and where it would come from. The point is to identify the care being discussed, rather than letting a headline amount define it.